Regeneron has two products in development based on aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[REF] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810 [REF].